SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer
SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer
复制标题
SRPX2 和 RAB31 是胰腺癌的有效预后生物标志物
DOI：
10.7150/jca.32072
复制
发表时间：
2019-01-01
影响因子：
3.9
通讯作者：
Wu, Chun-Tao
中科院分区：
文献类型：
--
作者：
Li, Hao;Zhang, Shi-Rong;Wu, Chun-Tao
简介：SRPX 2和RAB 31在肿瘤发生和转移中起重要作用，然而，它们在胰腺癌中的预后价值仍不清楚。本研究旨在探讨SRPX 2和RAB 31在胰腺癌诊断和预后中的潜在相互作用和影响。研究方法：通过Oncomine、Gene Expression Omnibus（GEO）和The Cancer Genome Atlas（TCGA）数据库的数据挖掘评估SRPX 2和RAB 31在胰腺肿瘤组织和细胞中的表达，并通过我们的临床数据库中的免疫组织化学（IHC）和Western blot验证结果。通过免疫荧光和免疫共沉淀（Co-IP）研究蛋白质-蛋白质相互作用。使用了来自患者的200个组织微阵列样本（79个训练样本和121个验证样本），这些患者接受了胰腺导管腺癌（PDAC）的根治性胰腺切除术。此外，分析SRPX 2和RAB 31与PDAC患者术后预后的关系。结果如下：SRPX 2和RAB 31在胰腺癌组织中的表达均显著增高，且两者之间存在显著正相关。Co-IP显示SRPX 2和RAB 31之间的直接相互作用。Kaplan-Meier分析显示，在训练集和验证集，SRPX 2和RAB 31的阳性表达与PDAC患者的无病生存期（DFS）和总生存期（OS）降低相关。多因素分析显示，第8版TNM分期、SRPX 2和RAB 31联合检测分别是训练集和验证集OS和DFS的独立预后因素。结论：联合检测SRPX 2和RAB 31可作为胰腺癌预后的重要指标。
Introduction: SRPX2 and RAB31 play important roles in tumorigenesis and metastasis; however, their prognostic value in pancreatic cancer remains unclear. This study aimed to investigate the potential interactions and effects of SRPX2 and RAB31 on the diagnosis and prognosis of pancreatic cancer. Methods: The expression of SRPX2 and RAB31 in pancreatic tumor tissues and cells was evaluated through database mining of the Oncomine, Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, and validated the results through immunohistochemistry (IHC) and Western blot in our clinical database. Protein-protein interactions were explored by immunofluorescence and Co-immunoprecipitation (Co-IP). Two hundred tissue microarray specimens from patients (79 training and 121 validation), who underwent curative pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) were used. Additionally, the association between the SRPX2 and RAB31 and prognosis of PDAC patients after surgery was analyzed. Results: The expression of SRPX2 and RAB31 was highly increased in pancreatic cancer, and there was a significant positive correlation between these two proteins. Co-IP showed the direct interaction between SRPX2 and RAB31. Kaplan-Meier analysis showed that positive expression of SRPX2 and RAB31 was associated with reduced disease-free survival (DFS) and overall survival (OS) of PDAC patients in the training set and the validation sets. Furthermore, multivariate analysis indicated that the 8th edition TNM stage and combination of SRPX2 and RAB31 were independent prognostic factors that associated with OS and DFS in the training, and the validation sets, respectively. Conclusions: The combination of SRPX2 and RAB31 can be important markers for the prognosis of pancreatic cancer.